Diagnostics Pipeline: MyOme and Artera Launch New Tests for Prostate Cancer Risk
The two assays identify threats prior to prostate cancer being diagnosed and after it has undergone extensive treatment, respectively
Keeps You Up-to-Date on New Diagnostic Tests, Testing Trends and Opportunities, and Emerging Test Technologies
The two assays identify threats prior to prostate cancer being diagnosed and after it has undergone extensive treatment, respectively
Platform enhances the interpretability of CBC-based machine-learning models
The assay detects the presence of three different proteins and is slightly more accurate than a test Quest released earlier this year
Current assays often miss diagnoses in the early stages of the disease, delaying treatment
The initiative is in conjunction with The Gift of Life registry and Doublemint Gum
FDA-approved tests like Intellisep and TriVerity demonstrate potential for early sepsis diagnosis
Clinical lab professionals will want to note the pros and cons each technology brings
The new blood-based assay avoids painful lumbar punctures and may quicken Alzheimer’s diagnoses
Model links tumor morphology with multiple genetic alterations, offering faster diagnostics
The intent of the at-home testing is to identify and treat issues such as postpartum depression and vitamin deficiencies
The company is offering whole panels and more than 1,000 assays in total to support the new products